Hypertrophy, Left Ventricular: all 162 studies

Page 2 of 2. Open to participants first (28), then studies with results posted, then the rest; newest registration first within each.

• Metabolic and Cardiovascular Effects of Armolipid Plus in Subjects With Metabolic SyndromeCompletedNCT02295176Not applicable
• Does Allopurinol Reduce Thickening of the Left Ventricle of the Heart in Patient With Treated Hypertension?CompletedNCT02237339Phase 4
• MetfoRmin and Its Effects on Left Ventricular Hypertrophy in Normotensive Patients With Coronary Artery DiseaseCompletedNCT02226510Phase 4
• Screening of Fabry Disease in Patients With Left Ventricular Hypertrophy Detected in EchocardiographyCompletedNCT02221141
• New-onset Diabetes and Left Ventricular Hypertrophy in Renal TransplantationCompletedNCT01976689
• Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED StudyCompletedNCT01951404Phase 4
• Remote Ischemic Preconditioning Induces Myocardial RISK Signaling Pathway in Patients Undergoing Valvular Heart SurgeryCompletedNCT01946087Phase 4
• Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular HypertrophyStatus unknownNCT01893788Phase 4
• Mineralocorticoid Receptor Antagonists in End Stage Renal DiseaseCompletedNCT01691053Phase 2
• The Effects of Active VItamin D on Left Atrial Volume IndexWithdrawnNCT01630408Not applicable
• Pulse Wave Analysis and Velocity in Patients With Chronic Renal Failure: a Cross-sectional Observational Study to Assess Association With Left Ventricular Hypertrophy, Uremic Toxins and Inflammation.CompletedNCT01579032
• Value of Cardiac Magnetic Resonance (CMR) Derived Parameters for Diagnosing Left Ventricular Non-compaction CardiomyopathyCompletedNCT01481298
• The Effects of Lowering Dialysate Sodium in Hypertensive Hemodialysis PatientsCompletedNCT01455974Not applicable
• Evaluation of Regional Myocardial Dynamics at Physical Stress in Essential HypertensionCompletedNCT01442116Not applicable
• Risk Factors for Coronary Artery Calcification and Left Ventricular Hypertrophy in Hemodialysis PatientsTerminatedNCT01427374
• Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular HypertrophyCompletedNCT01425411Phase 4
• Serum Sclerostin Levels, Cardiovascular Parameters and Carpal Tunnel Syndrome in Maintenance Hemodialysis PatientsStatus unknownNCT01382966
• Vitamin D Therapy to Reduce Cardiac Damage Among Vulnerable Hypertensive PatientsCompletedNCT01360476Not applicable
• Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)CompletedNCT01354613Not applicable
• CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy RegressionWithdrawnNCT01275352Phase 4
• Japan Central Aortic Pressure Prospective StudyStatus unknownNCT01243840
• The Effect of Heart Rate on Cardiac Index in Patients With Left Ventricular HypertrophyTerminatedNCT01241838Not applicable
• Impact of Physical Activity on Left Ventricular Mass and Lipid MetabolismTerminatedNCT01199211
• Belgian Screening Project for the Detection of Anderson-Fabry Disease in Hypertrophic CardiomyopathyCompletedNCT01198899
• Stenting of Renal Artery Stenosis in Coronary Artery Disease StudyStatus unknownNCT01173666Phase 3
• Glutamate and Diastolic Function in Patients Undergoing Aortic Valve RepairCompletedNCT01144039Phase 4
• The Cardiovascular Comorbidity in Children With Chronic Kidney Disease StudyStatus unknownNCT01046448
• Assessment of Bioimpedance and Vitamin D and LV Mass in PD Patients (FLUID Study)CompletedNCT01045980Phase 2
• Myocardial Protection With Perhexiline in Left Ventricular HypertrophyStatus unknownNCT00989508Phase 2/3
• Angiotensin-converting-enzyme (ACE) Inhibitors in HemodialysisCompletedNCT00985322Phase 3
• Diastolic Dysfunction in Aortic RegurgitationCompletedNCT00976625Not applicable
• Effects Of Volume Control Guided by Body Composition Monitor (BCM) on Blood Pressure and Cardiac Condition in Hemodialysis PatientsCompletedNCT00974857Phase 4
• Viennese Prevalence Study of Anderson-Fabry DiseaseStatus unknownNCT00871611
• Importance of Aldosterone in the Pathogenesis of Hypertensive Heart DiseaseCompletedNCT00865501Phase 3
• Effects of High Dose Atorvastatin in Patients With Surgical Aortic StenosisStatus unknownNCT00811330Phase 3
• Impact of In-centre Nocturnal Hemodialysis on Ventricular Remodeling and Function in End-stage Renal DiseaseCompletedNCT00718848
• Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction?CompletedNCT00688480Phase 4
• A Clinical Trial of IntensiVE DialysisCompletedNCT00649298Phase 4
• Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVHCompletedNCT00607633
• Attenuation of Cardiac Effects of Arteriovenous Fistula Creation With LosartanCompletedNCT00602004Not applicable
• Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist PegvisomantStatus unknownNCT00552851Phase 4
• Pathophysiological Mechanisms of Hypertensive LVH:Optimising RegressionCompletedNCT00518479Not applicable
• Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2 Study)Status unknownNCT00418041
• Comparison of Four and Eight Hours Dialysis Sessions in Thrice Weekly HemodialysisCompletedNCT00413803Phase 4
• Comparison of Post-dilution On-line Hemodiafiltration and HemodialysisCompletedNCT00411177Phase 4
• Access Creation for Hemodialysis: Association With Structural Changes of the HeartCompletedNCT00368147
• A Safety and Efficacy Study for Epoetin Alfa in Pre-dialysis Subjects.CompletedNCT00364260Phase 3
• Dallas Heart Study 2: Return Clinic Visit for the Dallas Heart Study CohortCompletedNCT00344903
• Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133)CompletedNCT00338260Phase 3
• EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal FailureCompletedNCT00338000Phase 4
• Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic InflammationCompletedNCT00307463Phase 4
• Effect of Angiotensin II Receptor Blockers (ARB) on Left Ventricular Reverse Remodelling After Aortic Valve Replacement in Severe Valvular Aortic StenosisStatus unknownNCT00294775Phase 3
• Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric PatientsCompletedNCT00221845Phase 3
• Active Vitamin D Effect on Left Ventricular HypertrophyTerminatedNCT00175149Phase 4
• Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk HypertensionCompletedNCT00139555Phase 4
• Hypertension in HemodialysisCompletedNCT00067665Not applicable
• The SILVER Study: Systolic Hypertension Interaction With Left Ventricular RemodelingCompletedNCT00045994Phase 2
• Cardiac MR of Subclinical CVD: Impact of AgeCompletedNCT00041418
• Racial Differences in the Coronary MicrocirculationCompletedNCT00005373
• Factors Contributing to Increased Left Ventricle Size in Patients With Abnormally Enlarged HeartsCompletedNCT00001878
• Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart DiseaseCompletedNCT00001632
• Long Term Effects of Enalapril and Losartan on Genetic Heart DiseaseCompletedNCT00001534

← Hypertrophy, Left Ventricular overview